Cediranib

Overview

The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Background

Indication

For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	2021/02/05	NCT04739800	Phase 2	Active, not recruiting	National Cancer Institute (NCI)
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma	2019/12/03	NCT04184518	Phase 2	Withdrawn	Grupo Español Multidisciplinar de Melanoma
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer	2019/09/16	NCT04090567	Phase 2	Recruiting	M.D. Anderson Cancer Center
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors	2019/02/22	NCT03851614	Phase 2	Active, not recruiting	University Health Network, Toronto
WIRE - Novel Treatments in Renal Cell Cancer	2018/11/14	NCT03741426	Phase 2	Recruiting	CCTU- Cancer Theme
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	2018/09/07	NCT03660826	Phase 2	Active, not recruiting	National Cancer Institute (NCI)
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?	2018/06/27	NCT03570437	Phase 2	UNKNOWN	University of Manchester
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy	2017/11/07	NCT03334617	Phase 2	Active, not recruiting	AstraZeneca
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib	2017/10/19	NCT03314740	Phase 2	Completed	Mario Negri Institute for Pharmacological Research
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients	2017/09/12	NCT03278717	Phase 3	UNKNOWN	University College, London

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access